Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VZV immunity and Varivax vaccination in immunocompromised renal disease patients
NL-OMON45220Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2014
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of varicella virus vaccine live in Varicella zoster infection (4 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: VZV-specific interferon-gamma ELISpot response and VZV-specific CD4+ and CD8+ T-cell proliferation. Started Nov 2014; status: active, not recruiting.
02
Drugs
varicella virus vaccine live
03
Conditions
Varicella zoster infection
Beyond the preview
Go deeper on NL-OMON45220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45220.